Analysis of current regulatory requirements for the quality of live bacterial vaccines and prospects for the improvement of vaccine quality control methods

INTRODUCTION. Currently, there are live bacterial vaccines (LBVs) for the prevention of tuberculosis and particularly dangerous infections, such as plague, tularaemia, anthrax, and brucellosis. LBVs provide reliable and long-lasting protection. The high effectiveness of LBVs is due to their ability to mimic natural infections. Despite significant differences in LBV compo­sitions, indications, and production species, the applicable quality control approaches share some common principles. At the same time, there are significant differences in methodological approaches to the assessment of a number of quality attributes, and some of these approaches require improvement and/or optimisation.

AIM. This study aimed to analyse current regulatory requirements for the quality of LBVs having different compositions and indications, to identify the quality attributes of LBVs with the associated quality control methods in need of improvement, and to explore promising pathways for further development in this area.

DISCUSSION. The review of regulatory standards and manufacturer specifications identified several quality attributes common to all LBVs. Vaccine identity was considered a key quality attribute. Motivated by the development of novel national diagnostic test systems, the authors analysed the performance of these test systems in practice to determine their potential for the identification of bacterial vaccines. In particular, immunochromatographic and serological techniques were successfully applied to the quality control of the tularaemia vaccine, a serological method was deemed suitable for brucellosis vaccines, and immunochromatography was recommended for plague and anthrax vaccines. A multiplex PCR method passed practical testing to be used for the quality control of BCG vaccines with reagents from Russian manufacturers. Flow cytometry was considered a promising technique for improving the quality control of LBVs in terms of viable units (tuberculosis and plague vaccines) and immunogenicity (plague vaccines).

CONCLUSIONS. This analysis of regulatory requirements highlighted problematic issues related to the standardised quality attributes of LBVs and methods for their assessment. The literature review results and the authors’ own data indicate promising directions for improving the methodology of LBV quality assessment. One of these promising directions is the use of Russian-made commercial test systems for LBV identification.

1. Medunitsyn NV, Katlinsky AV, Vorslov LO. Vaccinology: monograph. Moscow: Prakticheskaya meditsina; 2022 (In Russ.). EDN: FOLWPT

2. Dyatlov IA. Modern technological platforms for the development of vaccines against dangerous bacterial infections (part II). Bacteriology. 2022;7(4):5–9 (In Russ.). EDN: DNAHCO

3. Sayapina LV, Bondarev VP, Olefir YuV. Current state of vaccine prophylaxis of particularly dangerous infections. Problems of Particularly Dangerous Infections. 2016;(2):107–10 (In Russ.). https://doi.org/10.21055/0370-1069-2016-2-107-110

4. Shchipeleva IA, Kretenchuk OF, Korshenko VA, Markovskaya EI. Current status and prospects for specific plague prevention. Epidemiology and Infectious Diseases. 2022;12(1):101–9 (In Russ.). https://doi.org/10.18565/epidem.2022.12.1.101-9

5. Sycheva AA, Algazina BB, Polyakova AS. BCG vaccine and new tuberculosis vaccines. CTRI Bulletin. 2021;(S1): 27–8 (In Russ.). https://doi.org/10.7868/S2587667821050095

6. Kasina IV, Alekseeva SA, Nemirovskaya TI. Application of alternative identification methods for live tularaemia and brucellosis vaccines. Biological Products. Prevention, Diagnosis, Treatment. 2024;24(1):61–75 (In Russ.). https://doi.org/10.30895/2221-996X-2024-24-1-61-75

7. Kasina IV, Alekseeva SA, Nemirovskaya TI. Evaluation of the applicability of immunochromatography to the identification of live plague vaccines and the tularaemia allergen (Tularin). Biological Products. Prevention, Diagnosis, Treatment. 2023;23(2):231–40 (In Russ.). https://doi.org/10.30895/2221-996X-2023-23-2-231-240

8. Gostischeva SE, Abzaeva NV, Rakitina EL, Ponomarenko DG, Kostuchenko MV, Logvinenko OV, Kulichenko AN. Perspectives approach to the assessment of the quality of the vaccine plague live in terms of immunogenicity. Epidemiology and Vaccinal Prevention. 2019;18(1):50–4 (In Russ.). https://doi.org/10.31631/2073-3046-2019-18-1-50-54

9. Alekseeva SA, Kasina IV, Nemirovskaya TI. Comparative analysis of the results of live anthrax vaccine identification by immunofluorescence and immunochromatography. Biological Products. Prevention, Diagnosis, Treatment. 2024;24(3):348–56 (In Russ.). https://doi.org/10.30895/2221-996X-2024-24-3-348-356

10. Levi DT, Obukhov YuI, Aleksandrova NV, Volkova RA, Elbert EV, Alvarez Figeroa MV, et al. Identity and stability assessment of BCG vaccine by multiplex PCR. BIOpreparations. Prevention, Diagnosis, Treatment. 2016;16(1):49–54 (In Russ.). EDN: VSCURV

11. Sukhanova SM, Sayapina LV, Berdnikova ZE, Tikhonova AS, Klimov VI. Problems of assessment of live bacterial vaccine sterility. Problems of Particularly Dangerous Infections. 2019;(3):87–93 (In Russ.). https://doi.org/10.21055/0370-1069-2019-3-87-93

12. Kasina IV, Alekseeva SA, Nemirovskaya TI. Prospects for improving quality evaluation of the live brucellosis vaccine in terms of specific activity. BIOpreparations. Prevention, Diagnosis, Treatment. 2020;20(2):126–35 (In Russ.). https://doi.org/10.30895/2221-996X-2020-20-2-126-135

13. Guallar-Garrido S, Almiñana-Rapún F, Campo-Pérez V, Torrents E, Luquin M, Julián E. BCG substrains change their outermost surface as a function of growth media. Vaccines (Basel). 2021;10(1):40. https://doi.org/10.3390/vaccines10010040

14. Prados-Rosales R, Carreño LJ, Weinrick B, Batista-Gonzalez A, Glatman-Freedman A, Xu J, et al. The type of growth medium affects the presence of a mycobacterium capsule and is associated with differences in protective efficacy of BCG vaccination against Mycobacterium tuberculosis. J Infect Dis. 2016;214(3):426–37. https://doi.org/10.1093/infdis/jiw153

15. Pascoe J, Hendon-Dunn CL, Birch CPD, Williams GA, Chambers MA, Bacon J. Optimisation of Mycobacterium bovis BCG fermentation and storage survival. Pharmaceutics. 2020;12(9):900. https://doi.org/10.3390/pharmaceutics12090900

16. Gweon E, Choi C, Kim J, Kim B, Kang H, Park T, et al. Development of a new approach to determine the potency of Bacille Calmette-Guérin vaccines using flow cytometry. Osong Public Health Res Perspect. 2017;8(6):389–96. https://doi.org/10.24171/j.phrp.2017.8.6.06

17. Moghawry HM, Rashed ME, Gomaa K, AbdelGhani S, Dishisha T. Development of a fast and precise potency test for BCG vaccine viability using flow cytometry compared to MTT and colony-forming unit assays. Sci Rep. 2023;13(1):11606. https://doi.org/10.1038/s41598-023-38657-x

18. Abzaeva NV, Kuznetsova IV, Gostischeva SE, Zhirov AM, Kovalev DA, Kostrominov AV, et al. Prospects for using flow cytometry in the quality control of live plague vaccines. Biological Products. Prevention, Diagnosis, Treatment. 2023;23(4):560–9 (In Russ.). https://doi.org/10.30895/2221-996X-2023-23-4-560-569